Editas Medicine, Inc.

Editas Medicine, Inc.

2.16
CHF
-0.76
(-26.14%)
-0.52EPS
340.88MMarket Cap
Feb 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.05
0.19
0.34
0.68
0.41
1.56
0.38
0.29
1.03
0.39
0.46
0.43
Basic EPS, GAAP
- -
-0.83
-2.06
-3.03
-3
-2.35
-2.69
-1.99
-2.86
-3.23
-2.03
-2.89
-1.81
-0.62
Free Cash Flow per Basic Share
- -
-0.64
-0.19
-1.68
-0.29
-1.08
-0.94
-3.21
-2.55
-2.66
-1.81
-2.67
-1.88
-0.95
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.05
-0.43
-2.34
3.78
4.7
4.87
4.85
6.32
8.13
5.26
4.29
1.63
0.28
0.55
Tangible Book Value per Share
-0.05
-0.43
-2.34
3.78
4.7
4.87
4.85
6.32
8.13
5.26
4.29
1.63
0.28
0.55
Basic Weighted Avg Shares
36
15
36
32
40
47
50
58
67
68
76
82
88
116
Sales/Revenue/Turnover
- -
- -
2
6
14
32
21
91
26
20
78
32
41
50
Operating Margin (%)
- -
- -
-2,167.71
-1,605.62
-873.64
-356.1
-686.39
-148.61
-756.13
-1,146.26
-216.56
-739.37
-245.15
-166.97
Depreciation Expense
- -
- -
- -
1
3
3
3
4
5
6
6
6
5
2
Net Income, GAAP
- -
-14
-73
-97
-120
-110
-134
-116
-193
-220
-153
-237
-160
-72
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-4,475.14
-1,605.53
-876.49
-344.28
-651.43
-127.82
-753.61
-1,118.26
-196.13
-733.72
-395.01
-144.95
Working Capital
- -
5
138
154
295
339
404
361
460
297
278
212
118
130
LT Debt
2
- -
200
35
33
32
23
19
16
33
24
20
12
7
Total Equity
-2
-15
-83
135
208
236
262
394
554
361
349
134
27
85
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-70.22
-49.5
-53.65
-35.36
-40.65
-48.22
-43.17
-98.1
-198.14
-147.44

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
7
7
7
LT Borrowings
- -
- -
- -
LT Finance Leases
11
9
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
97
153
153
Market Capitalization
241
- -
409

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
128
218
202
Cash, Cash Equivalents & STI
124
212
190
Accounts Receivable, Net
3
3
8
Inventories
- -
- -
- -
Total Current Liabilities
40
68
72
Payables & Accruals
22
19
20
ST Debt
7
7
7
Deferred Revenue
8
40
40

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-27.14%
-27.72%
-79.68%
Free Cash Flow
124.36%
1.74%
-24.31%
Net Income, GAAP
12.91%
14.45%
-32.49%
Sales/Revenue/Turnover
100.56%
33.68%
25.39%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
- -
31
32
2025
5
4
8
25
41
2026
3
12
10
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.76
-0.83
-0.76
-0.55
-2.89
2025
-0.92
-0.63
-0.28
-0.06
-1.81
2026
-0.26
-0.15
-0.15
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Gilmore O’Neill
Full Time Employees
87
Sector
Health technology
Industry
Biotechnology
Address
11 Hurley Street Cambridge MA United States 02141
IPO Date
Feb 3, 2016
Business
Editas Medicine, Inc. (NASDAQ: EDIT) is a clinical-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative genomic medicines using CRISPR/Cas9 and CRISPR/Cas12a gene editing platforms to treat serious diseases, including rare genetic disorders, hyperlipidemia, ocular diseases, blood disorders, and cancers. The company offers a pipeline of in vivo and ex vivo gene editing therapies, such as EDIT-401, an investigational in vivo medicine targeting the LDLR gene via upregulation to achieve over 90% mean reduction in LDL-cholesterol levels in preclinical non-human primate studies; hematopoietic stem cell editing programs for non-malignant hematological diseases; and engineered cell therapies including CD19-directed allogeneic CAR-T programs for autoimmune diseases and oncology in collaboration with partners. Editas Medicine operates primarily in the United States with corporate headquarters in Cambridge, Massachusetts, and additional facilities in Boulder, Colorado, while advancing global clinical trials and partnerships. Founded in 2013 as Gengine, Inc. and renamed Editas Medicine shortly thereafter, the company targets patient populations underserved by existing therapies, including those with high cholesterol resistant to standard lipid-lowering drugs, through one-time, durable treatments delivered via lipid nanoparticles and other modalities. Recent developments include the nomination of EDIT-401 as a lead in vivo development candidate in September 2025, with proof-of-concept data presented at the European Society of Gene and Cell Therapy Congress in October 2025 and the American Heart Association Scientific Sessions in November 2025, demonstrating sustained LDL-C reductions; discontinuation of the reni-cel program in 2024 to prioritize in vivo efforts, incurring a $12.2 million restructuring charge; extension of its strategic collaboration with Bristol Myers Squibb in May 2024 for autologous and allogeneic alpha-beta T cell therapies targeting cancer and autoimmune diseases, including first IND/CTA acceptance for a CD19 HD Allo CAR-T program that triggered a milestone payment in 2025; and a October 2024 partnership with Genevant Sciences providing non-exclusive access to lipid nanoparticle technology for in vivo gene editing medicines against two undisclosed targets, valued at up to $238 million in milestones plus royalties.

Company News

  • Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study

  • Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates

  • Editas Medicine Announces Third Quarter 2026 Results and Business Updates

  • Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50 Day Moving Average – Here’s Why

  • Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

  • EDIT Set to Begin First-in-Human Study in Hypercholesterolemia

  • Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

  • Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50-Day Moving Average – Here’s Why

  • Bank of New York Mellon Corp Invests $851,000 in Editas Medicine, Inc. $EDIT

  • Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

  • Editas Medicine Reports Inducement Grants to New Chief Medical Officer

  • Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

  • Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

  • BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT

  • Editas Medicine to Participate in Upcoming Investor Conferences

  • Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

  • Editas Medicine Announces Second Quarter 2026 Results and Business Updates

  • Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.

  • The Healthcare M&A Wave

  • CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?